US Vitamin B4 (Choline Chloride 60%) prices increased significantly through April 2026 as tightening Asian export availability, higher freight costs, and strong downstream procurement supported a bullish market trend. Chinese fermentation plants reduced operating schedules due to maintenance and regulatory audits, while Indian manufacturers raised export quotations amid limited availability, tightening supply conditions for US importers. Demand from the biopharmaceutical and life-science sectors remained the primary driver, as formulators maintained forward purchasing to avoid validation delays. Nutraceutical manufacturers also increased Vitamin B4 procurement ahead of summer immunity campaigns, while the animal-feed segment showed comparatively weaker buying activity. Supply-side pressures further strengthened the market. Rising costs for fermentation-grade glucose, methanol, natural gas, and other intermediates increased Vitamin B4 production expenses, while higher trans-Pacific freight charges elevated landed import costs. During the first half of May, Asian suppliers continued to raise Vitamin B4 quotations due to elevated production and logistics expenses linked to higher crude oil prices due to the disruptions around the Strait of Hormuz. Looking ahead, ChemAnalyst expects Vitamin B4 prices to remain firm in the second half of May, supported by strong biopharma demand, elevated freight costs, and continued supply-side pressure from Asia.
US Vitamin B4 (Choline Chloride 60%) prices moved sharply higher through April 2026 as tightening Asian export availability, elevated freight costs, and sustained downstream procurement pushed the Vitamin B4 market into a firm bullish trend. Early in April, spot offers for Vitamin B4 from Asian exporters were already under pressure after Chinese fermentation plants reduced operating schedules due to scheduled maintenance and environmental audits. At the same time, Indian contract manufacturers raised Vitamin B4 quotations amid limited product availability and stronger export commitments, tightening supply conditions further for US importers.
Demand dynamics for Vitamin B4 remained uneven across downstream sectors during April, although the biopharmaceutical and life-science segment emerged as the key growth driver. Formulators involved in culture-media production and Phase III clinical validation programs maintained forward procurement of Vitamin B4 to avoid qualification delays and supply interruptions. Nutraceutical packers also increased Vitamin B4 purchases ahead of summer immunity campaigns and seasonal retail restocking, sustaining firm mid-month enquiries. In contrast, the animal-feed and feed-additive segment reduced discretionary buying, partially offsetting broader demand momentum. According to ChemAnalyst, inventory coverage for Vitamin B4 in the US remained thin throughout April, with most buyers holding less than six weeks of stock, increasing market sensitivity to supply disruptions.
Supply-side pressures amplified the bullish sentiment in the Vitamin B4 market. Chinese production curbs at two major fermentation facilities, driven by maintenance work and regulatory audits, reduced export availability and tightened prompt Vitamin B4 offers in international markets. Indian suppliers also faced shipping delays, extending lead times for CFR Los Angeles cargoes. Rising feedstock and energy costs further pressured Vitamin B4 production economics, as higher prices for fermentation-grade glucose, ethylene oxide-derived intermediates, methanol, and natural gas significantly increased manufacturing overheads. In addition, Shanghai-to-Los Angeles freight rates increased during April, adding approximately USD 25/MT to Vitamin B4 landed costs and reinforcing higher import quotations across the US market.
During the first half of May, Vitamin B4 prices remained elevated as Asian exporters continued to increase quotations amid rising production expenses and higher freight charges. Mainstream Chinese producers maintained firm Vitamin B4 offers, while trading-market prices also stayed strong due to sustained export demand and ongoing cost inflation. Market participants reported that disruptions around the Strait of Hormuz and elevated crude oil prices further increased freight and insurance expenses, supporting the continued firmness in Vitamin B4 pricing.
Looking ahead, ChemAnalyst analysts expect Vitamin B4 prices could increase further in the second half of May as biopharma and nutraceutical demand remains firm and supply chains continue to face pressure from high crude oil prices, elevated freight charges, and rising production costs. Continued disruptions linked to the Strait of Hormuz situation may further tighten logistics availability and increase transit times for Vitamin B4 shipments. However, ChemAnalyst projects that some easing may emerge during June and July as earlier procurement activity and inventory normalization reduce immediate buying pressure, although market direction will remain dependent on Asian production trends, freight conditions, and feedstock cost movements.
